Travere Therapeutics (TVTX) Cash from Financing Activities (2013 - 2026)

Travere Therapeutics' Cash from Financing Activities history runs 14 years deep, the most recent figure standing at $4.2 million for Q1 2026.

• Quarterly Cash from Financing Activities rose 13.07% year-over-year to $4.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$33.0 million (down 122.96% YoY) and the FY2025 annual result came in at -$33.5 million, down 124.0% from the prior year.
• Cash from Financing Activities was $4.2 million for Q1 2026 at Travere Therapeutics, down from $26.7 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $217.6 million in Q1 2023 and bottomed at -$65.3 million in Q3 2025.
• A 5-year average of $26.4 million and a median of $1.5 million in 2025 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2024 — Cash from Financing Activities jumped 112092.74% — and 2025, when it sank 142141.3%.
• Travere Therapeutics' Cash from Financing Activities stood at $1.2 million in 2022, then plunged by 89.26% to $124000.0 in 2023, then soared by 112092.74% to $139.1 million in 2024, then tumbled by 80.82% to $26.7 million in 2025, then slumped by 84.24% to $4.2 million in 2026.
• Business Quant data shows TVTX's Cash from Financing Activities at $4.2 million in Q1 2026, $26.7 million in Q4 2025, and -$65.3 million in Q3 2025.